Rosuvastatin , compared with placebo , reduced sCD14 ( -10.4 % vs 0.5 % , P = 0.006 ) , lipoprotein-associated phospholipase A2 ( -12.2 % vs -1.7 % , P = 0.0007 ) , and IP-10 ( -27.5 vs -8.2 % , P = 0.03 ) levels after 48 weeks .